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P U B L I S H E D B Y E L S E V I E R I N C .LETTERS TO THE EDITORTransthoracic Echocardiography Guidance
for TAVR Under Monitored Anesthesia CareTwo- and three-dimensional transesophageal echo-
cardiography (TEE) has played a vital role in trans-
catheter aortic valve replacement (TAVR) procedures
for evaluating aortic annulus and root geometry,
device selection, procedural guidance, and assess-
ment of prosthetic valve function. The use of intra-
procedural TEE, however, often necessitates the use
of general anesthesia (GA) with endotrachealTABLE 1 Baseline Characteristics and Outcomes
Moderate Sedatio
(n ¼ 47)
Age, yrs 82.70  7.89
Female 26 (56.52)
EuroSCORE II, % 7.79  5.87
Body mass index, kg/m2 26.30  4.23
Diabetes mellitus 12 (25.53)
Lung disease (moderate/severe) 18 (38.29)
Chronic kidney disease (stage 4 or 5) 8 (17.02)
Hypertension 45 (95.74)
Peripheral vascular disease 4 (8.51)
Prior stroke 2 (4.25)
Prior transient ischemic attack 3 (6.38)
Coronary artery disease 25 (53.19)
Prior CABG 11 (23.40)
Prior PCI 19 (40.42)
Prior myocardial infarction 7 (14.89)
Pre-existing deﬁbrillator 3 (6.38)
Pre-existing pacemaker 8 (17.02)
Prior atrial ﬁbrillation or atrial ﬂutter 16 (34.04)
Procedure time, min 144.26  28.96
In-hospital death 1 (2.17)
Stroke —
Multiple TAVR valve deployment 2 (4.34)
Post-procedure PVR (SAPIEN-THV)
None/trace 3 (33.33)
Mild 6 (66.67)
Moderate —
Post-procedure PVR (CoreValve)
None/trace 20 (52.63)
Mild 15 (39.47)
Moderate 3 (7.89)
ICU length of stay, h 64.51  29.81
Length of hospital stay, days 7.19  3.84
Values are mean  SD or n (%).
CABG ¼ coronary artery bypass graft; ICU ¼ intensive care unit; PCI ¼ percutaneous c
valve replacement.intubation, which may increase procedural time and
the potential risks of complications associated with
GA. An alternate strategy is the use of transthoracic
echocardiography (TTE) so that the TAVR procedure
is completed under controlled sedation and anal-
gesia, also referred to as monitored anesthesia care
(MAC) (1). In this letter, we summarize our initial
experience in performing TTE-guided TAVR under
MAC. The procedural outcomes from a group of
patients who underwent TEE-guided TAVR under GA
were matched on the basis of the mean EuroSCORE II
values and used as a comparison cohort.
We included all patients who underwent TAVR
through the transfemoral approach (either percuta-
neous or direct arterial cut down) from May 1, 2012 ton General Anesthesia
(n ¼ 64) p Value
82.03  8.22 0.667
41 (64.06) 0.462
8.56  4.15 0.440
27.60  6.55 0.236
18 (28.12) 0.920
20 (31.00) 0.258
7 (10.93) 0.517
64 (100.00) 0.177
7 (10.93) 0.757
5 (7.81) 0.697
4 (6.25) —
31 (48.43) 0.764
13 (20.31) 0.887
20 (31.25) 0.424
8 (12.50) 0.920
2 (3.12) 0.649
9 (14.06) 0.862
15 (23.43) 0.310
193.75  62.35 <0.001
3 (4.91) 0.636
2 (3.27) 0.507
3 (4.91) —
35 (68.62) 0.063
13 (25.49)
3 (5.88)
9 (75.00)
3 (25.00) 0.200
0 (—)
65.30  31.37 0.895
8.00  6.97 0.839
oronary intervention; PVR ¼ paravalvular regurgitation; TAVR ¼ transcatheter aortic
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380August 30, 2014. Both TEE and TTE were performed
with the use of a Vivid 9 imaging platform (GE
Healthcare, Waukesha, Wisconsin). Valve sizing was
determined by means of multidetector computed to-
mography. Fluoroscopic guidance was used in all
cases. Anesthesia was administered and monitored by
a cardiac anesthesiologist. General anesthesia con-
sisted of tracheal intubation facilitated with a para-
lytic and induction agent. Anesthesia was maintained
with inhaled anesthetics and intravenous opioids.
MAC was administered with the use of infusions of
either dexmedetomidine or propofol in combination
with intravenous opioids and local anesthesia (2.0%
lidocaine with 0.5% bupivacaine) applied to the
femoral access site. Both cohorts were monitored
with insertion of a central venous catheter, pulmo-
nary artery catheter, temporary right ventricular
pacemaker, and invasive arterial blood pressure
catheter. The 2 groups were compared by use of
standard statistical methods for continuous and cat-
egorical variables, with differences considered sta-
tistically signiﬁcant at p < 0.05.
The study population included 111 patients, of
whom 64 underwent TAVR with TEE (GA) and 47
underwent TTE (MAC). The Edwards-SAPIEN THV
(Edwards Lifesciences, Irvine, California) was placed
in 50 of the TEE cohort and in 9 of the TTE cohort. The
remainder of the patients received the CoreValve
prosthesis. Two patients in the TTE cohort were
converted to TEE because of inadequate transthoracic
windows. The baseline characteristics are presented
in Table 1.
Outcome data were statistically similar between
the cohorts with regard to procedural success, degree
of paravalvular regurgitation, need for additional
valve implantation, or complications such as peri-
procedural stroke or death (Table 1). Procedural time
was longer in the TEE (GA) cohort (p < 0.001) and
related to the time needed for weaning off the
ventilator. The median length of stay was 6 days in
both groups and was not affected by type of valve.
The similar length of stay was related to our institu-
tional policy that required monitoring for 48 h in the
intensive care unit, irrespective of the type of anes-
thesia or valve implanted.
Although this is a retrospective study with a
modest sample size and relative heterogeneity with
respect to type of valve implanted, our data suggest
that TAVR can be safely performed with the use of
TTE guidance under MAC. These ﬁndings require
larger, prospective, multicenter studies to more
clearly deﬁne potential beneﬁts such as shorter pro-
cedural times, decreased length of stay, and reduced
hospital costs.Partho P. Sengupta, MD*
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analysis. BMC Med 2014;12:41.Dobutamine Stress Echocardiography for
Risk Stratiﬁcation of Patients With
Low-Gradient Severe Aortic Stenosis
Undergoing TAVRPatients with low-gradient severe aortic stenosis
(LGSAS) have dismal outcomes when medically
managed and although their long-term outcomes are
improved with surgery, their risk of death is signiﬁ-
cantly higher than that of their counterparts with
mean transaortic gradient (DP) >40 mm Hg (1). Low-
dose dobutamine stress echocardiography (DSE), by
determining whether ﬂow reserve (FR) is present
with inotropic stimulation, has proven useful in
enhancing risk stratiﬁcation of this high-mortality
subgroup undergoing surgical aortic valve replace-
ment (SAVR) (2,3). Whether the lack of FR in patients
undergoing transcatheter aortic valve replacement
(TAVR) similarly portends poor prognosis is unknown
and was explored in this study.
Electronic medical records of patients who under-
went TAVR for severe AS at Emory University
Hospital from January 2009 to March 2013 were
reviewed. Demographics and clinical characteristics
including comorbidities, outcomes, and echocardio-
graphic data were retrospectively collected. LGSAS
was deﬁned as DP <40 mm Hg and an aortic valve
area (AVA) #1.0 cm2, with either reduced or normal
ejection fraction (EF) on baseline transthoracic
echocardiogram. Forty-nine patients with LGSAS who
